Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 10/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801335 | 0.78 | KMT2A (0.42) | CA2ALDH1A1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL2595400 | 0.76 | ACHE (0.48) | PDCD1LG2CD274USP28ALDH1A1MPO | |
| SCHEMBL16701643 | 0.74 | MPO (0.64) | CA2ALDH1A1MPOKMT2ACYP1A2 | |
| SCHEMBL4323675 | 0.74 | P2RX7 (0.43) | PDCD1LG2CD274CA2ALDH1A1KMT2A | |
| SCHEMBL4323680 | 0.74 | P2RX7 (0.43) | PDCD1LG2CD274CA2ALDH1A1KMT2A | |
| SCHEMBL4331911 | 0.74 | P2RX7 (0.43) | PDCD1LG2CD274CA2ALDH1A1KMT2A | |
| SCHEMBL13242873 | 0.73 | USP28 (0.41) | PDCD1LG2CD274USP28ALDH1A1USP25 | |
| SCHEMBL19208040 | 0.73 | CYP3A4 (0.48) | PDCD1LG2CD274ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL29781598 | 0.73 | CYP3A4 (0.48) | PDCD1LG2CD274ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL1241765 | 0.73 | CES2 (0.38) | CA2ALDH1A1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | PDCD1LG2 4018/4885CD274 3969/4885USP28 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.